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Abstract. 
Background: Previous studies demonstrated that GC (gemcitabine and cisplatin) provided a 
similar survival advantage as M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) 
for urothelial carcinoma of the bladder (UCB), and had a better safety profile and improved 
tolerability. However, no clinical clues in selection of first-line chemotherapy regimen were 
suggested. This study aims to determine whether different sites of metastasis and chemother-
apy regimens affected the prognosis of patients with metastatic UCB. 
Methods: Patients with metastatic UCB were retrospectively reviewed. Data on clinical char-
acteristics, progression free survival (PFS), overall survival (OS), overall response rate (ORR) 
and complete response (CR) rate were analyzed. 
Results: Between 2000 and 2012, a total of 76 patients with metastatic UCB were enrolled. 
The median age was 64.5 years and the median follow-up period was 13.6 months. Of these 
patients, 37 had lymph node-only metastasis (LOM) and 39 had non-LOM. The median sur-
vival was significantly longer for UCB patients with LOM. The median PFS was 10.0 months 
for LOM and 4.3 months for non-LOM (P = < 0.01), while the median OS was 16.9 months 
for LOM and 10.5 months for non-LOM (P = < 0.01). The ORR and CR rate were both sig-
nificantly higher in patients with LOM than in those with non-LOM. Subgroup analysis sug-
gested that UCB patients with LOM treated with M-VAC had a better survival. The median 
PFS was 16.4 months in the M-VAC group and 8.7 months in the GC group (P = 0.08), while 
the median OS was 23.1 months in the M-VAC group and 16.0 months in the GC group (P = 
0.03). The CR rate remained significant.  
Conclusions: UCB patients with LOM, especially those treated with M-VAC, had better sur-
vival outcomes and greater CR rate than those with non-LOM. However, the sample size of 
this study was quite small and analyzed on a retrospective basis. Further prospective random-
ized studies are warranted. 
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原著論文  
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中文摘要 
目的：過去的研究指出 M-VAC 及 GC 皆為膀胱泌尿上皮癌標準的第一線化學治療，兩者
具有相似的存活期，但 GC 似乎有較高的安全性與接受度。然而在現行的臨床指引中，並
未明確的指出這兩種化學治療在臨床使用上的選擇。本篇研究的目的，主要是想要找出
轉移部位與化療效果之間的關連性。 
方法：我們回溯性的收集了在我們機構接受治療的轉移性膀胱泌尿上皮癌的患者，並逐
一分析患者的臨床資料、無惡化存活期、整體存活期、整體反應率及完全反應率。 
結果：在 2000 年和 2012 年間，總共有 76 的患者被納入我們的研究，平均年紀為 64.5 歲，
平均追蹤期為 13.6 個月。其中，37 個患者為僅有淋巴轉移，39 個患者為非僅有淋巴轉移。
比起非僅有淋巴轉移，膀胱泌尿上皮癌併僅有淋巴轉移患者有較佳的生存預後，無惡化
存活期中位數為 10.0 個月比 4.3 個月 (P = < 0.01)，整體存活率中位數為 16.9 個月比 10.5
個月 (P = < 0.01)，客觀反應率及完全反應率也都有顯著性的差異。次群體分析顯示膀胱
泌尿上皮癌併僅有淋巴轉移之患者接受 M-VAC 治療比起接受 GC 治療有較佳的預後，無
惡化存活期中位數為 16.4 個月比 8.7 個月 (P = < 0.01)，整體存活期中位數為 23.1 個月比
16.0 個月 (P = < 0.01)，完全反應率亦達顯著性的差異。 
結論：比起非僅有淋巴轉移，膀胱泌尿上皮癌併僅有淋巴轉移的患者有較佳的生存預後
及完全反應率，這個效益在接受 M-VAC 治療的患者身上更為顯著。我們的觀察需要更多
前瞻性隨機分派臨床試驗加以確認。 
 
關鍵字: 膀胱泌尿上皮癌、僅有淋巴轉移、M-VAC 化學治療、GC 化學治療、生存預後、
反應率 
 
INTRODUCTION 
Urothelial carcinoma of the bladder (UCB) is the 
leading malignancy of the urinary tract. A previous 
study reported the ratio of urothelial carcinoma of the 
renal pelvis, ureter and bladder in Taiwan to be 1 : 
2.08 : 6.72 from 1983 to 1998 [1]. The age standard-
ized incidence rate of bladder cancer in Taiwan was 
2.68 per 100,000 in 2010 [2]. At least 25% of patients 
harbored lymph node metastasis at the time of diagno-
sis [3]. The gold standard chemotherapy for metastatic 
UCB is a platinum-based chemotherapy regimen [4]. 
Physicians from Memorial Sloan-Kettering Cancer 
Center first reported results with methotrexate, vin-
blastine, doxorubicin (adriamycin) and cisplatin 
(M-VAC) regimen in the 1980s. The response rate was 
72% in 121 cases of bidimensionally measurable dis-
eases [5]. In the 2000s, Maase et al reported compara- 
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Table 1. Baseline clinical characteristics of 76 patients with metastatic urothelial carcinoma of the bladder 
  LN-only metastasis Non-LN-only metastasis P 
  N = 37 N = 39   
Gender       0.52 
Male 24 65% 28 72%   
Female 13 35% 11 28%   
Age       0.58 
≦60 12 32% 15 38%   
>60 25 68% 24 62%   
Initial clinical or pathologic stage       0.93 
Stage 1-2 12 32% 13 33%   
Stage 3-4 25 68% 26 67%   
Grade       N/A 
Low grade 0 0% 0 0%   
High grade 37 100% 39 100%   
Histology     0.25 
Pure urothelial carcinoma 33 89% 31 79%  
Urothelial carcinoma with variants 4 11% 8 21%  
Disease status upon enrollment     N/A 
Locally advanced 0 0% 0 0%  
Metastatic disease 37 100% 39 100%  
Chemotherapy regimen       0.29 
M-VAC 10 27% 15 39%   
GC  27 73% 24 61%   
Carboplatin-containing       0.08 
No 32 86% 38 97%   
Yes 5 14% 1 3%   
Intravesical chemotherapy       0.88 
No 25 68% 27 69%   
Yes 12 32% 12 31%   
Palliative radiotherapy       0.95 
No 24 65% 25 64%   
Yes 13 35% 14 36%   
≧2nd line chemotherapy     0.12 
No 32 87% 28 72%   
Yes 5 14% 11 28%   
Abbreviation: M-VAC, Methotrexate/Vincristine/Doxorubicin/Cisplatin or Carboplatin;  
GC, Gemcitabine/Cisplatin or Carboplatin; LN, lymph node; N/A, not applicable 
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ble results with gemcitabin and cisplatin (GC) treat-
ment. GC chemotherapy provided a similar response 
rate to M-VAC chemotherapy (46% and 49%, respec-
tively) with a better safety profile and improved tol-
erability [6,7]. Therefore, M-VAC and GC both be-
came widely used regimens for metastatic UCB. 
However, over the past decades, no advances have 
been made in the treatment of metastatic UCB [4]. It 
is of interest to find out either M-VAC or GC may 
offer a better response rate and survival of patients 
with UCB. Previous studies had demonstrated that a 
single metastatic site was a good prognostic factor for 
UCB [8,9], while liver metastasis was a poor prognos-
tic factor [10,11]. However, there are no definitive 
conclusions regarding the relationship between meta-
static site and chemotherapy response. Therefore, our 
study aims to determine whether sites of metastasis 
and chemotherapy regimens affected prognosis. This 
will be useful in selection of chemotherapy regimen in 
our clinical practice. 
 
PATIENTS AND METHODS 
 
Study Population 
This retrospective study has been approved by the 
Institutional Review Board. Patients with metastatic 
UCB receiving M-VAC or GC as their first-line 
chemotherapy between 2000 and 2012 at Kaohsiung 
Chang Gung Memorial Hospital were enrolled in this 
study. In patients with impaired renal function tests (at 
least chronic kidney disease stage 3), carboplatin was 
used instead of cisplatin. All the primary site tumors 
were removed, either by transurethral resection of 
bladder tumor, partial cystectomy or radical surgery. 
All tumors were histologically confirmed to be 
urothelial carcinoma, including all histological vari-
ants. Tumor staging was determined according to the 
7th edition of the American Joint Committee on Can-
cer/Union Internationale Contre le Cancer TNM clas-
sification [12]. Patients were stratified into two groups, 
lymph node-only metastasis (LOM) and non-LOM. 
The diagnosis of LOM was made radiographically. 
Patients with lymph node (LN) metastasis without 
evidence of visceral metastasis on chest CT, ab-
dominal CT, and bone scan were allocated to the LOM 
group. Non-LOM refers to visceral-only, visceral plus 
LN, local recurrence plus LN and local recurrence 
plus visceral metastasis. LNs were categorized as lo-
coregional, retroperitoneal or supraclavicular LNs. 
The locoregional LNs consisted of perivesical, ingui-
nal, external iliac, internal iliac and common iliac LNs 
[13]. In order to compare the response to chemother-
Table 2. Metastatic sites of 76 UCB patients with LOM and non-LOM 
37 UCB patients with LOM N %
     Locoregional only 10 27%
     Retroperitoneal only 12 32%
     Locoregional + retroperitoneal 13 35%
     Retroperitoneal + supraclavicular 2 5%
39 UCB patients with non-LOM   
     Visceral only 12 31%
     Visceral metastasis + lymph node metastasis 13 33%
     Local recurrence + visceral metastasis 6 15%
     Local recurrence + lymph node metastasis 8 21%
Abbreviation: UCB, urothelial carcinoma of the bladder;  
LOM, lymph node-only metastasis 
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apy, patients with LOM were then divided according 
to chemotherapy regimen. The chemotherapy regimen 
was decided at the discretion of the treating physician. 
Exclusion criteria included previous systemic chemo-
therapy for this disease (including adjuvant chemo-
therapy), dose reduction to below 70% of the standard 
dose, an incomplete first chemotherapy cycle, and 
inability to evaluate chemotherapy response. 
 
Chemotherapy Schedule 
Patients getting the GC treatment received a 
28-day cycle of the gemcitabine and cisplatin regimen: 
gemcitabine 1,000 mg/m2 over 30 minutes on days 1, 
8, and 15 plus cisplatin 70 mg/m2 over 3-4 hours on 
day 2. Patients getting the M-VAC treatment received 
a 28-day cycle of the methotrexate, vinblastine, doxo-
rubicin and cisplatin regimen: methotrexate 30 mg/m2 
on days 1, 15, and 22; vinblastine 3 mg/m2 on days 2, 
15, and 22; doxorubicin 30 mg/m2 on day 2; and cis-
platin 70 mg/m2 over 3-4 hours infusion on day 2. 
Cisplatin was administered with adequate pre- and 
post-hydration. Patients with poor renal function re-
ceived carboplatin instead of cisplatin, whose dose 
was calculated by AUC x (eGFR+25), AUC = 5. Cy-
cles were repeated at least every 28 days. In both 
groups, cycles were not started unless WBC ≧3,000 
/uL and platelet count ≧100,000 /uL. Doses were 
also adjusted for nonhematologic toxicity, including 
mucositis. Prophylactic use of leucovorin and growth 
factors was not allowed. 
 
Outcome Measurement 
The statistical endpoints were progression-free 
survival (PFS), overall survival (OS), overall response 
rate (ORR), complete response (CR) rate and severe 
adverse events (SAE). The cause of death was deter-
mined by a retrospective chart review. PFS was cal-
culated from the starting date of the chemotherapy 
until the date that the disease worsened or recurred. 
OS was calculated from the starting date of the chem-
otherapy until the date of death or the last contact 
when the patients were still alive at the time of the 
follow-up visit. ORR was defined as the ratio of CR 
and partial response according to RECIST (version 
1.1). SAE was defined as severe adverse events lead-
ing to hospitalization or death within 30 days after the 
last session of chemotherapy. 
 
Statistical Analyses 
Patients’ clinicopathologic characteristics were 
compared between both groups using the Pearson χ2 
test. Kaplan-Meier curves with a log-rank test were 
used to estimate the PFS and OS for all patients. All 
statistical tests were two-sided. P-values < 0.05 were 
considered to be statistically significant. All statistical 
analyses were performed using the SPSS v19.0. 
Table 3. Results for 76 patients with metastatic urothelial carcinoma of the bladder after chemotherapy 
  LN-only metastasis Non-LN-only metastasis P 
  N = 37 N = 39  
Median progression free survival (m) 10 4.3  <0.01
Median overall survival (m) 16.9  10.5 <0.01
Objective response rate (%) 87% 36% <0.01
Complete remission 12 (32%) 2 (5%) <0.01
Partial response 20 (54%) 12 (31%)  
Stable disease 5 (14%) 14 (36%)  
Progression disease 0 (0%) 11 (28%)  
Abbreviation: LN, lymph node 
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Table 4. Baseline clinical characteristics of 37 patients with metastatic urothelial carcinoma of the bladder and 
LN-only metastasis, stratified by chemotherapy regimen 
  M-VAC GC P 
  N = 10 N = 27   
Gender         0.69 
Male 7 70% 17 63%   
Female 3 30% 10 37%   
Age         0.17 
≦60 5 50% 7 26%   
>60 5 50% 20 74%   
Initial clinical or pathologic stage         0.01 
Stage 1-2 0 0% 12 44%   
Stage 3-4 10 100% 15 56%   
Grade         N/A 
Low grade 0 0% 0 0%   
High grade 10 100% 27 100%   
Histology     0.92 
Pure urothelial carcinoma 9 90% 24 89%  
Urothelial carcinoma with variants 1 10% 3 11%  
Disease status upon enrollment     N/A 
Locally advanced 0 0% 0 0%  
Metastatic disease 10 100% 27 100%  
Carboplatin-containing         0.70 
No 9 90% 23 86%   
Yes 1 10% 4 14%   
Intravesical chemotherapy         0.85 
No 7 70% 18 67%   
Yes 3 30% 9 33%   
Palliative radiotherapy         0.71 
No 6 60% 18 67%   
Yes 4 40% 9 33%   
≧2nd line chemotherapy       0.70 
No 9 90% 23 85%   
Yes 1 10% 4 15%   
Abbreviation: M-VAC, Methotrexate/Vincristine/Doxorubicin/Cisplatin or Carboplatin;  
GC, Gemcitabine/Cisplatin or Carboplatin; LN, lymph node; N/A, not applicable 
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Figure 1. Kaplan-Meier plots of progression-free survival (PFS) and overall survival (OS) for 76 patients with 
metastatic urothelial carcinoma of the bladder, stratified by lymph node (LN)-only metastasis and 
Non-LN-only metastasis. (A) PFS, (B) OS 
 
 
RESULTS 
 
Patients and Clinical Characteristics 
Our study consisted of 76 patients with a median 
age of 64 years and a median follow-up period of 13.6 
months. There were 37 patients with LOM and 39 
with non-LOM. The characteristics of these patients 
are shown in Table 1. Of these patients, 68% of LOM 
patients and 67% of non-LOM patients had initial 
clinical or pathologic stage 3-4 (P = 0.93). Forty-one 
patients underwent radical surgery, 2 partial cystecto-
my and 33 transurethral resection of bladder tumor 
(TURBT). Two patients received partial cystectomy 
were because of multiple co-morbidities. Of the 33 
TURBTs, 16 were palliative for tissue proof and 17 
were curative. All patients had metastatic disease upon 
enrollment. All patients with LOM had a single organ 
metastasis, while 69% patients of non-LOM had me-
tastases to two or more organs. Twenty-seven percent 
of LOM patients received M-VAC treatment and 73% 
received GC treatment, while 39% of non-LOM pa-
tients received M-VAC treatment and 61% received 
GC treatment (P = 0.29). A trend was observed to-
wards carboplatin-containing chemotherapy, account-
ing for 14% of LOM patients and 3% of non-LOM 
patients (P = 0.08). Moreover, there were no signifi-
cant differences between gender, age, grade, histology 
variants, intravesical chemotherapy, palliative radio-
therapy, and the percentage of patients receiving se-
cond line chemotherapy or more. Twenty-seven per-
cent of LOM patients had locoregional LN metastasis 
and 73% had distant LN metastasis, while 31% of pa-
tients with non-LOM had non-LN involvement and 
69% had LN involvement (Table 2). 
 
Survival Outcome 
During the follow-up period, 30 (81%) LOM pa-
tients and 36 (92%) non-LOM patients died. Tumor 
progression was the major cause of death in both 
groups, accounting for 93% of deaths in LOM patients 
and 97% in non-LOM patients. The survival outcomes 
for 76 patients with metastatic UCB after chemother- 
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Figure 2. Kaplan-Meier plots of progression-free survival (PFS) and overall survival (OS) for 76 patients with 
metastatic urothelial carcinoma of the bladder after chemotherapy, stratified by lymph node (LN) me-
tastasis and chemotherapy regimen. (A) PFS, (B) OS 
 
 
apy are summarized in Table 3, stratified by LOM and 
non-LOM. The median PFS was 10 months in LOM 
patients and 4.3 months in non-LOM patients (P = < 
0.01, Figure 1A) , while the median OS was 16.9 
months in LOM patients and 10.5 months in 
non-LOM patients (P = < 0.01, Figure 1B). The ORR 
and CR rate were significantly higher in patients with 
LOM than non-LOM (ORR: 87% vs. 36%, P = <0.01; 
CR rate: 32% vs. 5%, P = <0.01). After that, subgroup 
analysis was performed in order to evaluate the re-
sponse to chemotherapy regimen. Comparison of pa-
tients with LOM by chemotherapy regimen revealed 
similar clinical characteristics except for initial stage, 
as depicted in Table 4. The initial clinical or patholog-
ic stage was more advanced in M-VAC group than GC 
group. The survival outcomes for 37 UCB patients 
with LOM are summarized in Table 5. The median 
PFS was 16.4 months for M-VAC and 8.7 months for 
GC (P = 0.08, Figure 2A), while the median OS was 
23.1 months for M-VAC and 16 months for GC (P = 
0.03, Figure 2B). The difference of ORR was insig-
nificant, but the CR rate was significantly higher in 
the M-VAC group. There was only 1 patient with 
M-VAC treatment developing SAE, which was insig-
nificant as compared with GC treatment. 
 
DISCUSSION 
To the best of our knowledge, there are no guide-
lines for the selection of M-VAC or GC as first-line 
chemotherapy in patients with metastatic UCB. Cur-
rent guidelines only suggest that both M-VAC and GC 
are potent first-line chemotherapy regimens for pa-
tients with metastatic UCB [14]. No further recom-
mendations for clinical selection of these two regi-
mens have been given. Our study shows that M-VAC 
seems superior to GC for UCB patients with LOM. 
The median OS of LOM patients reached a significant 
survival difference between M-VAC and GC, while 
the median PFS only showed a trend towards im-
proved survival with M-VAC treatment. This insignif-
icance might be due to limited sample size. This ob-
servation may be helpful for us to select a proper 
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chemotherapy regimen for patients with metastatic 
UCB. 
To date, there are no conclusive studies regarding 
the chemotherapy response by metastatic site in pa-
tients with UCB. Previous studies demonstrated a re-
sponse rate of 66% and 77% with M-VAC and high 
dose M-VAC, respectively, in patients with retroperi-
toneal LN metastasis versus 29% and 33% with ex-
tranodal sites metastasis [15,16]. Our study compared 
the response rate between M-VAC and GC for UCB 
patients with LOM. The ORR was not significantly 
different between these two groups, but the CR rate 
was significantly higher for M-VAC. This suggests 
that for patients with LOM, M-VAC may be a better 
choice. Results from a recent study on perioperative 
chemotherapy were also consistent with our results. A 
trend toward improved response was seen in the 
M-VAC group [17]. 
Prognostic factors for patients with metastatic 
UCB have been reported by several retrospective 
studies. A single organ metastasis is considered as a 
good prognostic factor [8,9]. The sites of metastasis 
are also independent prognostic factors for survival. 
Visceral metastasis such as liver metastasis is a poor 
prognostic factor for survival [10,11], while lymph 
node metastasis is associated with better prognosis. In 
patients with LOM, 20.9% of patients were alive at 5 
years compared to 6.8% of those with visceral metas-
tasis [7]. Our observation also suggested that LOM 
patients had better survival than non-LOM patients. 
The ORR and CR rate were higher in the LOM group. 
The better prognosis associated with LOM has also 
been reported in several other types of cancer. For 
patients with metastatic prostate cancer, men with liv-
er metastases had the worst survival, followed by 
those with lung metastases, bone with node metastases, 
bone-only metastasis, and node-only disease, who 
exhibited the best survival [18]. For patients with 
metastatic or recurrent esophageal squamous cell car-
cinoma, LOM was also a significant prognostic fac-
tors for longer survival [19]. 
As far as we know, this is the first study showing 
that LOM was associated with better prognosis than 
non-LOM in patients with metastatic UCB. The sur-
vival outcomes with M-VAC treatment were promis-
ing. However, our study still has some limitations in-
herent to any retrospective collection of data. Fur-
thermore, this is a single-institutional experience, 
which can sometimes be biased. Our case number is 
small because patients with metastatic UCB often 
Table 5. Results for 37 patients with metastatic urothelial carcinoma of the bladder and LN-only metastasis, 
stratified by chemotherapy regimen 
  M-VAC GC P 
  N = 10 N = 27   
Median progression free survival (m) 16.4 8.7 0.08 
Median overall survival (m) 23.1 16 0.03 
Objective response rate (%)  90% 85% 0.7 
Complete remission 6 (60%) 6 (22%) 0.03 
Partial response 3 (30%) 17 (63%)   
Stable disease 1 (10%) 4 (15%)   
Progression disease 0 (0%) 0 (0%)   
Severe adverse effects 10% 0% 0.1 
Abbreviations: M-VAC, Methotrexate/Vincristine/Doxorubicin/Cisplatin or Carboplatin; GC, Gemcitabine/Cisplatin or Carboplatin; 
LN, lymph node 
 
 
M. C. Hsieh et al./JCRP 1(2014) 197-207 205
have older ages and poor renal function, which render 
them unfit for chemotherapy. As such, our study suc-
ceeds in finding a survival difference between M-VAC 
and GC chemotherapy in UCB patients with LOM. 
Current practice guidelines only suggest that M-VAC 
and GC are both potent first-line chemotherapy regi-
mens for metastatic UCB. Our study makes further 
recommendations in UCB patients with LOM. 
In conclusion, our study suggests that UCB pa-
tients with LOM have a better survival and higher CR 
rate than those with non-LOM. LOM is a good prog-
nostic factor for metastatic UCB. From the viewpoints 
of chemotherapy regimen, M-VAC provides a higher 
response and a similar safety profile than GC for UCB 
patients with LOM disease. Further prospective, ran-
domized control trials are warranted to validate these 
results. 
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